FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stéphane Culine

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Daniel Satgé; Alix Clémenson; Pascal Clémenson; Martine Hennequin; Joris Mortier; Motoi Nishi; Cécile Pacaut; Stéphane Culine
A mucoepidermoid carcinoma in a young man with intellectual disability: review of oral cancer in people with intellectual disability.
Stéphane Culine
Cetuximab in advanced bladder cancer.
Damien Pouessel; Pierre Mongiat-Artus; Stéphane Culine
Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stéphane Culine (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Daniel Satgé; Alix Clémenson; Pascal Clémenson; Martine Hennequin; Joris Mortier; Motoi Nishi; Cécile Pacaut; Stéphane Culine
A mucoepidermoid carcinoma in a young man with intellectual disability: review of oral cancer in people with intellectual disability.
Oral surgery, oral medicine, oral pathology and oral radiology 2013;115(5):e22-7.
2013: Stéphane Culine
Cetuximab in advanced bladder cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(12):1614-5.
2013: Damien Pouessel; Pierre Mongiat-Artus; Stéphane Culine
Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?
Critical reviews in oncology/hematology 2013;85(3):288-94.
2012: Daniel Satgé; Motoi Nishi; Stéphane Culine; Martine Hennequin
Awareness on oral cancer in people with intellectual disability.
Oral oncology 2012;48(11):e44-5.
2012: Tamás Kullmann; Christine Le Maignan; Andrea Szabó; Hélène Gauthier; Stéphane Culine
[Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Orvosi hetilap 2012;153(35):1385-8.
2012: Stéphane Culine; Catherine Delbaldo; Elias Assaf; Linda Bouaita; Zineb Sellam; Muriel Verlinde-Carvalho; Damien Pouessel
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Anticancer research 2012;32(9):3949-52.
2012: Damien Pouessel; Frank Priou; Liji Shen; Gwenaelle Gravis; Stéphane Oudard; Stéphane Culine
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
Bulletin du cancer 2012;99(7-8):731-41.
2012: Tamás Kullmann; Stéphane Culine
[Treatment of anaemia in medical oncology].
Orvosi hetilap 2012;153(25):973-7.
2012: Hélène Gauthier; Damien Pouessel; Guilhem Bousquet; Stéphane Culine
Abiraterone acetate withdrawal syndrome: does it exist?
Case reports in oncology 2012;5(2):385-7.
2012: Marine Gross-Goupil; M C Kaminsky; A Laplanche; T Lesimple; A Lortholary; S Négrier; N Penel; Frank Priou; J Provencal; E Voog; E Blot; Jeannine Bouzy; L Chaigneau; Stéphane Culine; A Fourcade; Karim Fizazi
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
European journal of cancer (Oxford, England : 1990) 2012;48(5):721-7.
2012: Damien Pouessel; Stéphane Culine
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Anti-cancer drugs 2012;23(1):141-2.
2011: Stéphane Culine; Aude Fléchon; Aline Guillot; Nadine Houédé; Florence Joly; Sylvestre Le Moulec; Laurent Mignot; Stéphane Oudard; Damien Pouessel; Alain Ravaud; Frédéric Rolland; Sophie Gourgou
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
European urology 2011;60(6):1251-7.
2011: Aude Fléchon; Gwenaelle Gravis; F Joly; Stéphane Oudard; D Perol; Damien Pouessel; Frank Priou; Sylvie Zanetta; G Deplanque; Jean Pierre Droz; Pierre Fargeot; C Ferlay; Philippe Beuzeboc; Stéphane Culine
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(11):2476-81.
2011: Damien Pouessel; Stéphane Culine; Pierre Mongiat-Artus
Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
European urology 2011;60(4):870-1.
2011: Elias Assaf; Isabelle Baumgaertner; Linda Bouaita; Catherine Delbaldo; Julien Grenier; Muriel Paul; Damien Pouessel; Zineb Sellam; Iradj Sobhani; Claude Tayar; Muriel Verlinde-Carvalho; Stéphane Culine
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Oncology 2011;80(5-6):301-6.
2011: Yves Allory; Stéphane Culine; Alexandre de la Taille
Kidney cancer pathology in the new context of targeted therapy.
Pathobiology : journal of immunopathology, molecular and cellular biology 2011;78(2):90-8.
2011: Thibault de La Motte Rouge; Patricia Pautier; Annie Rey; Pierre Duvillard; Pierre Kerbrat; Frédéric Troalen; Philippe Morice; Christine Haie-Meder; Stéphane Culine; Catherine Lhommé
Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.
European journal of cancer (Oxford, England : 1990) 2011;47(2):175-82.
2011: Hervé Wallerand; Jean-Christophe Bernhard; Stéphane Culine; Philippe Ballanger; Grégoire Robert; Robert E Reiter; Jean-Marie Ferrière; Alain Ravaud
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.
Urologic oncology 2011;29(1):4-11.
2010: François Haab; Sébastien Beley; Jean-nicolas CORNU; Stéphane Culine; Olivier Cussenot; C Hennequin
[Urinary and sexual disorders following localised prostate cancer management].
Bulletin du cancer 2010;97(12):1537-49.
2010: Damien Pouessel; Stéphane Culine
[Actualities in prostate cancer in ASCO annual meeting 2010].
Bulletin du cancer 2010;97(12):1563-72.
2010: Guillaume Ploussard; stephane terry; Pascale Maillé; Yves Allory; Nanor Sirab; Laurence Kheuang; Pascale Soyeux; Nathalie Nicolaiew; Estelle Coppolani; Bernard Paule; Laurent Salomon; Stéphane Culine; Ralph Buttyan; Francis Vacherot; Alexandre de la Taille
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Cancer research 2010;70(22):9253-64.
2010: Damien Pouessel; Helena Huguet; François Iborra; Xavier Rebillard; Didier Ayuso; Catherine Becht; Stéphane Culine
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
Anticancer research 2010;30(11):4711-5.
2010: Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.
Molecular cancer therapeutics 2010;9(6):1740-54.
2010: Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1850-5.
2010: D Pouessel; juliette thariat; jean leon lagrange; N Mottet; Stéphane Culine
[Perioperative strategies in patients with muscle invasive bladder cancer].
Bulletin du cancer 2010;97 Suppl Cancer de la vessie():5-9.
2010: Damien Pouessel; Jean-Jacques Patard; Stéphane Culine
[Advanced renal carcinomas with special situations. How to treat them?].
Bulletin du cancer 2010;97():83-90.
2009: C Delbaldo; C Delbado; P Caillet; D Pouessel; E Paillaud; Stéphane Culine
[Specificities of chemotherapy in elderly cancer patients].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2009;19 Suppl 3():S100-5.
2009: Yann Neuzillet; Stéphane Culine; Jean-Jacques Patard
Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.
International journal of urology : official journal of the Japanese Urological Association 2009;16(11):855-61.
2009: Joaquim Bellmunt; Christine Théodore; Tomasz Demkov; Boris Komyakov; Lisa Sengelov; Gedske Daugaard; Armelle Caty; Joan Carles; Agnieszka Jagiello-Gruszfeld; Oleg Karyakin; François-Michel Delgado; Patrick Hurteloup; Eric Winquist; Nassim Morsli; Yacine Salhi; Stéphane Culine; Hans von der Maase
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4454-61.
2009: Florence Joly; Nadine Houédé; Sabine Noal; Christine Chevreau; Frank Priou; Paule Chinet-Charrot; Frédéric Rolland; Aude Fléchon; Michel Henry-Amar; Stéphane Culine
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.
Clinical genitourinary cancer 2009;7(2):E28-33.
2009: Stéphane Culine
Androgen deprivation therapy for node-positive prostate cancer: adjuvant does not mean salvage.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2888; author reply 2888.
2009: Laurence Bastien; Stéphane Culine; Bernard Paule; Souhil Ledbai; Jean-Jacques Patard; Alexandre de la Taille
Targeted therapies in metastatic renal cancer in 2009.
BJU international 2009;103(10):1334-42.
2009: Benjamin Besse; Dominique Grunenwald; Aude Fléchon; Armelle Caty; Christine Chevreau; Stéphane Culine; Christine Théodore; Karim Fizazi
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
The Journal of thoracic and cardiovascular surgery 2009;137(2):448-52.
2009: Stéphane Culine
Prognostic factors in unknown primary cancer.
Seminars in oncology 2009;36(1):60-4.
2009: Jean Trédaniel; C Becht; M Bekradda; H De Cremoux; Jérôme Alexandre; F Chomy; S Szyldergemajn; Y Yataghene; Stéphane Culine
An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients.
Lung cancer (Amsterdam, Netherlands) 2009;63(2):259-63.
2009: Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.
PloS one 2009;4(10):e7542.
2009: Daniel Satgé; Annie J Sasco; Steven Day; Stéphane Culine
A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21.
Urologia internationalis 2009;82(3):296-300.
2009: Jean-Jacques Patard; Rodolphe Thuret; Avakian Raffi; Brigitte Laguerre; Karim Bensalah; Stéphane Culine
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
European urology 2009;55(1):237-9; quiz 239.
2008: Damien Pouessel; Stéphane Culine
[Towards the individualisation of prescriptions in oncology: urogenital cancers].
Bulletin du cancer 2008;95(10):975-8.
2008: Alain Ravaud; Hervé Wallerand; Stéphane Culine; Jean-Christophe Bernhard; Patricia Fergelot; Karim Bensalah; Jean-Jacques Patard
Update on the medical treatment of metastatic renal cell carcinoma.
European urology 2008;54(2):315-25.
2008: Thibault de La Motte Rouge; Patricia Pautier; Pierre Duvillard; Annie Rey; Philippe Morice; Christine Haie-Meder; Pierre Kerbrat; Stéphane Culine; F Troalen; Catherine Lhommé
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(8):1435-41.
2008: Jean-Jacques Patard; Damien Pouessel; Karim Bensalah; Stéphane Culine
Targeted therapy in renal cell carcinoma.
World journal of urology 2008;26(2):135-40.
2008: Damien Pouessel; Stéphane Culine; Gregory Verhoest; Jean-Jacques Patard
[Renal cell carcinoma and antiangiogenic therapies].
Presse médicale (Paris, France : 1983) 2008;37(4 Pt 2):628-33.
2008: Nicolas Mottet; Sophie Rousmans; Stéphane Culine
[Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy].
Bulletin du cancer 2008;95(2):205-34.
2008: Stéphane Culine
Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis.
European urology 2008;53(2):273-4.
2008: Damien Pouessel; Stéphane Culine
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
European urology 2008;53(2):376-81.
2008: Stéphane Culine; Andrew Kramar; Christine Théodore; Lionel Geoffrois; Christine Chevreau; Pierre Biron; Binh Bui Nguyen; JF Héron; Pierre Kerbrat; Armelle Caty; Rémi Delva; Pierre Fargeot; Karim Fizazi; Jeannine Bouzy; Jean Pierre Droz
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):421-7.
2007: Nicolas Mottet; Christophe Avances; Cyrille Bastide; Stéphane Culine; François Iborra; Agnes Lesourd; Frédérique Michel; Jérome Rigaud
[Penile tumors].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2007;17(6):1049-62.
2007: Nicolas Mottet; Stéphane Culine; François Iborra; Christophe Avances; Cyrille Bastide; Agnes Lesourd; Frédérique Michel; Jérome Rigaud
[Testicular tumors].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2007;17(6):1035-45.
2007: Christophe Massard; Jean-Jacques Voigt; Agnès Laplanche; Stéphane Culine; Alain Lortholary; Roland Bugat; Christine Theodore; Frank Priou; Marie-Christine Kaminsky; Thierry Lesimple; Xavier Pivot; Bruno Coudert; Jean-Yves Douillard; Yacine Merrouche; Karim Fizazi
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
British journal of cancer 2007;97(7):857-61.
2007: Jean-Jacques Patard; Damien Pouessel; Stéphane Culine
New therapies in renal cell carcinoma.
Current opinion in supportive and palliative care 2007;1(3):174-9.
2007: Jean-Jacques Patard; Grégory Verhoest; Stéphane Culine
[Prognostic factors in localized and in metastatic renal cell carcinomas].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2007;17(5):912-6.
2007: Stéphane Culine; Mounira El Demery; Pierre-Jean Lamy; François Iborra; Christophe Avancès; Frédéric Pinguet
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
The Journal of urology 2007;178(3 Pt 1):844-8; discussion 848.
2007: Stéphane Culine
Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
European urology 2007;52(1):9-10.
2007: François Iborra; Christophe Avances; Stéphane Culine; A Houlgatte; N Mottete
[What about lombo-aortic curage in the treatment of testicle cancer?].
Annales d'urologie 2007;41(3):116-26.
2007: Stéphane Oudard; Eugeniu Banu; Annick Vieillefond; Laure Fournier; Frank Priou; Jacques Medioni; Adela Banu; Brigitte Duclos; Frédéric Rolland; Bernard Escudier; Nina Arakelyan; Stéphane Culine
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
The Journal of urology 2007;177(5):1698-702.
2007: Stéphane Culine; Pierre Kerbrat; Andrew Kramar; Christine Théodore; Christine Chevreau; Lionel Geoffrois; Nguyen Binh Bui; Jean Pény; Armelle Caty; Rémi Delva; Pierre Biron; Karim Fizazi; Jeannine Bouzy; Jean Pierre Droz
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(5):917-24.
2007: Damien Pouessel; Blandine Gallet; Frédéric Bibeau; Christophe Avancès; François Iborra; Pierre Sénesse; Stéphane Culine
Liver metastases in prostate carcinoma: clinical characteristics and outcome.
BJU international 2007;99(4):807-11.
2007: S Vieillot; Damien Pouessel; N M de Champfleur; Catherine Becht; Stéphane Culine
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):608-9.
2007: Jean Pierre Droz; Andrew Kramar; Pierre Biron; José-Luis Pico; Pierre Kerbrat; Jean Pény; Hervé Curé; Christine Chevreau; Christine Théodore; Jeannine Bouzy; Stéphane Culine
Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
European urology 2007;51(3):739-46; discussion 747-8.
2007: Stéphane Culine
[Chemotherapy for metastatic germ cell tumours of the testis].
La Revue du praticien 2007;57(4):385-8.
2007: Jean-Sébastien Annicotte; Stéphane Culine; Lluis Fajas
[Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy].
Bulletin du cancer 2007;94(2):135-7.
2007: Damien Pouessel; Stéphane Culine
[Angiogenesis targeting in renal carcinomas].
Bulletin du cancer 2007;94(7 Suppl):F223-6.
2006: Damien Pouessel; Stéphane Culine
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Expert review of anticancer therapy 2006;6(12):1761-7.
2006: Jean-Sébastien Annicotte; Irena Iankova; Stéphanie Miard; Vanessa Fritz; David Sarruf; Anna Abella; Marie-Laurence Berthe; Danièle Noël; Arnaud Pillon; François Iborra; Pierre Dubus; Thierry Maudelonde; Stéphane Culine; Lluis Fajas
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Molecular and cellular biology 2006;26(20):7561-74.
2006: Aude Fléchon; Karim Fizazi; Sophie Gourgou-Bourgade; Christine Théodore; Philippe Beuzeboc; Lionel Geoffrois; Nicolas Mottet; Christine Chevreau; Stéphane Culine
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
Anti-cancer drugs 2006;17(6):705-8.
2006: Mounira El Demery; Damien Pouessel; Christophe Avancès; François Iborra; Xavier Rebillard; Antoine Faix; Bruno Ségui; Olivier Delbos; Didier Ayuso; Stéphane Culine
[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2006;16(3):320-3.
2006: Stéphane Culine; C Theodore; M De Santis; B Bui; Tomasz Demkow; J Lorenz; Frédéric Rolland; F-M Delgado; B Longerey; Nicholas James
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
British journal of cancer 2006;94(10):1395-401.
2006: Philippe Mougenot; Françoise Bressolle; Stéphane Culine; Isabelle Solassol; Sylvain Poujol; Frédéric Pinguet
In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
Anticancer research 2006;26(3B):2197-203.
2006: Stéphane Culine
Editorial comment.
European urology 2006;49(4):703.
2006: Jean-Louis Davin; Stéphane Culine; Michel Soulié; Vincent Ravery; Marc Zerbib
[Prostatic cancer and pelvic node involvement: a unambiguous disease?].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2006;16(2 Suppl 1):239-56.
2006: Stéphane Culine; François Iborra; Nicolas Mottet; Christophe Avancès; Bertrand de Graeve; Pascal Volpé; Jacques Vignoud; Jean-Pierre Bringer; Michel Marroncle; Loïc Le Pellec; Didier Ayuso; Eric Jansen; Antoine Faix; Xavier Rebillard
Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
American journal of clinical oncology 2006;29(2):148-52.
2006: Christophe Avancès; Nicolas Mottet; Aba Mahatmat; Eliette Chapuis; Isabelle Serre; Stéphane Culine
Prognostic factors for first recurrence in patients with retroperitoneal sarcoma.
Urologic oncology 2006;24(2):94-6.
2006: Stéphane Culine
[Oxaliplatin and genito-urinary tumors].
Bulletin du cancer 2006;93 Suppl 1():S41-3.
2006: Philippe Mougenot; Michel Fabbro; Françoise Bressolle; Damien Pouessel; Stéphane Culine; Frédéric Pinguet
Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
Oncology reports 2006;15(1):237-41.
2005: Damien Pouessel; Simon Thezenas; Stéphane Culine; Catherine Becht; Pierre Senesse; Marc Ychou
Hepatic metastases from carcinomas of unknown primary site.
Gastroentérologie clinique et biologique 2005;29(12):1224-32.
2005: Aude Fléchon; Stéphane Culine; Christine Théodore; Jean Pierre Droz
Pattern of relapse after first line treatment of advanced stage germ-cell tumors.
European urology 2005;48(6):957-63; discussion 963-4.
2005: David Azria; Nicolas Magné; Abderrahim Zouhair; Pierre Castadot; Stéphane Culine; Marc Ychou; Roger Stupp; Paul Van Houtte; Jean-Bernard Dubois; Mahmut Ozsahin
Radiation recall: a well recognized but neglected phenomenon.
Cancer treatment reviews 2005;31(7):555-70.
2005: Isabelle Solassol; Laetitia Caumette; Françoise Bressolle; Frédéric Garcia; Simon Thézenas; Cécile Astre; Stéphane Culine; Rémi Coulouma; Frédéric Pinguet
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
Oncology reports 2005;14(4):1029-36.
2005: Stéphane Culine; Frédéric Michel; Laurence Rocher; Nicolas Mottet; Jean-Louis Davin
[Follow-up of testicular germ cell tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2005;15(4):593-6.
2005: Stéphane Culine
[Chemotherapy of penile carcinomas].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2005;15(4 Suppl 2):829-30.
2005: Isabelle Solassol; Françoise Bressolle; Laetitia Caumette; Frédéric Garcia; Sylvain Poujol; Stéphane Culine; Frédéric Pinguet
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Therapeutic drug monitoring 2005;27(4):491-8.
2005: Jean-Pierre Lotz; B Bui; F Gomez; Christine Théodore; Armelle Caty; Karim Fizazi; Gwenaelle Gravis; Rémi Delva; Jean Peny; Patrice Viens; B Duclos; T De Revel; Hervé Curé; Joseph GLIGOROV; S Guillemaut; C Ségura; S Provent; Jean Pierre Droz; Stéphane Culine; Pierre Biron
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):411-8.
2004: Stéphane Culine
[Management of stage I nonseminomatous germ cell tumours after orchiectomy].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2004;14(6):1112-8.
2004: Nicolas Mottet; Christophe Avances; Cyrille Bastide; Stéphane Culine; François Ibora; Georges Kouri; Agnes le Sourd; Frederique Michel; Pierre Pabot du Chatelard; Laurence Rocher
[Penile tumors].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2004;14(4 Suppl 1):903, 905-11.
2004: Nicolas Mottet; Christophe Avances; Cyrille Bastide; Stéphane Culine; François Ibora; Georges Kouri; Agnes le Sourd; Frederique Michel; Laurence Rocher
[Testicular tumors].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2004;14(4 Suppl 1):891, 893-901.
2004: David Azria; M Coelho; Christel Larbouret; Claire Lemanski; Antoine Serre; Marc Ychou; André Pèlegrin; Jean-Bernard Dubois; Stéphane Culine
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2004;8 Suppl 1():S106-13.
2004: Jacques Bonneterre; Véronique Dieras; Michèle Tubiana-Hulin; Philippe Bougnoux; Marie-Edith Bonneterre; Thierry Delozier; F Mayer; Stéphane Culine; N Dohoulou; B Bendahmane
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
British journal of cancer 2004;91(8):1466-71.
2004: Karim Fizazi; Stéphane Culine; Andrew Kramar; Robert J Amato; Jeannine Bouzy; Isan Chen; Jean Pierre Droz; Christopher J Logothetis
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(19):3868-76.
2004: Adina Marti; Stéphane Culine; Patrice Carde; Bertrand Paugam; Karim Fizazi
Familial primary mediastinal nonseminomatous germ-cell tumors.
Urologic oncology 2004;22(5):421-4.
2004: Stéphane Culine; Gilles Romieu; Michel Fabbro; Catherine Becht; Didier Cupissol; Catherine Guillemare; Jean-Pierre Bleuse; Véronique Lotz; Sophie Gourgou
Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study.
Cancer 2004;101(1):178-82.
2004: Philippe Mougenot; Frédéric Pinguet; Michel Fabbro; Stéphane Culine; Sylvain Poujol; Cécile Astre; Françoise Bressolle
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2004;53(6):503-12.
2004: K Zurbonsen; Françoise Bressolle; Isabelle Solassol; Pierre-Jean Aragon; Stéphane Culine; Frédéric Pinguet
Simultaneous determination of dexamethasone and 6 beta-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):421-9.
2004: Simon Thezenas; Jacqueline Duffour; Stéphane Culine; Andrew Kramar
Five-year change in statistical designs of phase II trials published in leading cancer journals.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1244-9.
2004: Damien Pouessel; Stéphane Culine; Catherine Becht; Marc Ychou; Gilles Romieu; Michel Fabbro; Didier Cupissol; Frédéric Pinguet
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Cancer 2004;100(6):1257-61.
2004: Chantal Rodary; V Pezet-Langevin; S Garcia-Acosta; Thierry Lesimple; Alain Lortholary; Marie-Christine Kaminsky; Jaafar Bennouna; Stéphane Culine; Hugues Bourgeois; Karim Fizazi
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP).
European journal of cancer (Oxford, England : 1990) 2004;40(4):521-8.
2003: Thierry Lesimple; Jean-Jacques Voigt; Anne Bataillard; Jean-Michel Coindre; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Pierre Bedossa; Gérard Bertrand; Roland Bugat; Karim Fizazi
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site].
Bulletin du cancer 2003;90(12):1071-96.
2003: David Azria; Christel Larbouret; Bruno Robert; Stéphane Culine; Marc Ychou; Pierre Verrelle; Jean-Bernard Dubois; André Pèlegrin
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Bulletin du cancer 2003;90 Spec No():S202-12.
2003: Sylvain Poujol; Frédéric Pinguet; Françoise Malosse; Cécile Astre; Marc Ychou; Stéphane Culine; Françoise Bressolle
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Clinical chemistry 2003;49(11):1900-8.
2003: Stéphane Culine; Alain Lortholary; Jean-Jacques Voigt; Roland Bugat; Christine Théodore; Frank Priou; Marie-Christine Kaminsky; Thierry Lesimple; Xavier Pivot; Bruno Coudert; Jean-Yves Douillard; Yacine Merrouche; Jelila Allouache; Alain Goupil; Sylvie Négrier; Juliette Viala; Peter Petrow; Jeannine Bouzy; Agnès Laplanche; Karim Fizazi
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3479-82.
2003: Dany Gholam; Karim Fizazi; Marie-José Terrier-Lacombe; Pascale Jan; Stéphane Culine; Christine Theodore
Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Cancer 2003;98(4):745-52.
2003: Roland Bugat; Anne Bataillard; Thierry Lesimple; Jean-Jacques Voigt; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Céline Laforêt; Pierre Bedossa; Gérard Bertrand; Jean-Michel Coindre; Karim Fizazi
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).
British journal of cancer 2003;89 Suppl 1():S59-66.
2003: J P Droz; X Muracciole; N Mottet; Mahmoud Ould-Kaci; Jean-Michel Vannetzel; N Albin; Stéphane Culine; J-M Rodier; Jean-Louis Misset; S Mackenzie; Esteban Cvitkovic; G Benoit
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1291-8.
2003: Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean Pierre Droz; Dominique Mery-Mignard; Stéphane Culine; Bernard Escudier
A phase II study of irinotecan in patients with advanced renal cell carcinoma.
Cancer 2003;98(1):61-5.
2003: Damien Pouessel; Stéphane Culine; Catherine Becht; Gilles Romieu; Michel Fabbro; Marc Ychou; Didier Cupissol; Frédéric Pinguet
Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.
Anticancer research 2003;23(3C):2801-4.
2003: Christophe Avances; Chokri Oumaya; Victoire Granger; Olivier Dubon; Jean Christophe Gris; Stéphane Culine; Pierre Costa
[Prostate cancer and acute disseminated intravascular coagulation. Therapeutic management based on three cases].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2003;13(2):308-12.
2003: Stéphane Culine; Xavier Rebillard; François Iborra; Nicolas Mottet; Antoine Faix; Didier Ayuso; Frédéric Pinguet
Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study.
Anticancer research 2003;23(2C):1903-6.
2003: Maud Boucaud; Frédéric Pinguet; Stéphane Culine; Sylvain Poujol; Cécile Astre; Roberto Gomeni; Françoise Bressolle
Modeling plasma and saliva topotecan concentration time course using a population approach.
Oncology research 2003;13(4):211-9.
2002: Stéphane Culine; Andrew Kramar; Mahasti Saghatchian; Roland Bugat; Thierry Lesimple; Alain Lortholary; Yacine Merrouche; Agnès Laplanche; Karim Fizazi
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4679-83.
2002: Roland Bugat; Anne Bataillard; Thierry Lesimple; Jean-Jacques Voigt; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Céline Laforêt; Pierre Bedossa; Gérard Bertrand; Jean-Michel Coindre; Karim Fizazi
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
Bulletin du cancer 2002;89(10):869-75.
2002: Christophe Avancès; W Jacot; P Sénesse; Stéphane Culine
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer.
The Journal of urology 2002;168(4 Pt 1):1496.
2002: Bernard Escudier; Jean Pierre Droz; Frédéric Rolland; M J Terrier-Lacombe; G Gravis; Philippe Beuzeboc; B Chauvet; Christine Chevreau; Jean-Christophe Eymard; Thierry Lesimple; Yacine Merrouche; Stéphane Oudard; Frank Priou; C Guillemare; Sophie Gourgou; Stéphane Culine
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
The Journal of urology 2002;168(3):959-61.
2002: Joseph GLIGOROV; Thierry André; Christelle Epaud; Stéphane Culine
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Bulletin du cancer 2002;89 Spec No():S134-44.
2002: Stéphane Culine
[Gemcitabine and urogenital tumors].
Bulletin du cancer 2002;89 Spec No():S102-6.
2002: Stéphane Culine
The present and future of combination chemotherapy in bladder cancer.
Seminars in oncology 2002;29(3 Suppl 9):32-9.
2002: Amélie Gauvin; Frédéric Pinguet; Stéphane Culine; Cécile Astre; Roberto Gomeni; Françoise Bressolle
A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer.
Anti-cancer drugs 2002;13(5):473-80.
2002: Laurent Zelek; Paul-Henri Cottu; Michèle Tubiana-Hulin; Jean-Michel Vannetzel; Philippe Chollet; Jean-Louis Misset; N Chouaki; Michel Marty; Erick Gamelin; Stéphane Culine; Véronique Dieras; S Mackenzie; Marc Spielmann
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2551-8.
2002: David Azria; William Jacot; Patricia Prost; Stéphane Culine; Marc Ychou; Claire Lemanski; Jean-Bernard Dubois
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
Bulletin du cancer 2002;89(4):369-79.
2002: Stéphane Culine
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2002;12(1 Suppl 2):31-5.
2002: Stéphane Culine; Michel Fabbro; Marc Ychou; Gilles Romieu; Didier Cupissol; Frédéric Pinguet
Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
Cancer 2002;94(3):840-6.
2002: Ashraf Montazeri; Stéphane Culine; Brigitte Laguerre; Frédéric Pinguet; François Lokiec; Nicolas Albin; Alain Goupil; Régine Déporte-Féty; Roland Bugat; Pierre Canal; Etienne Chatelut
Individual adaptive dosing of topotecan in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):394-9.
2002: Amélie Gauvin; Frédéric Pinguet; Stéphane Culine; Cécile Astre; Didier Cupissol; Françoise Bressolle
Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Cancer chemotherapy and pharmacology 2002;49(1):48-56.
2001: Maud Boucaud; Frédéric Pinguet; Sylvain Poujol; Gilles Romieu; Didier Cupissol; Cécile Astre; Stéphane Culine; Françoise Bressolle
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2357-64.
2001: Karim Fizazi; S Tjulandin; Roberto Salvioni; Josep Ramón Germà-Lluch; Jeannine Bouzy; D Ragan; Carsten Bokemeyer; Arthur Gerl; Aude Fléchon; J S de Bono; Sally P Stenning; Alan Horwich; Jörg Pont; P Albers; Ugo De Giorgi; mark bower; A Bulanov; Giorgio Pizzocaro; Jorge Aparicio; Craig Nichols; Christine Théodore; Jörg Thomas Hartmann; Hans-J Schmoll; S B Kaye; Stéphane Culine; Jean Pierre Droz; Cédric Mahé
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2647-57.
2001: Stéphane Culine; Marc Ychou; Michel Fabbro; Gilles Romieu; Didier Cupissol
5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.
Anticancer research 2001;21(2B):1455-7.
2001: J Alexandre; Karim Fizazi; Cédric Mahé; Stéphane Culine; Jean Pierre Droz; Christine Théodore; Marie-José Terrier-Lacombe
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse.
European journal of cancer (Oxford, England : 1990) 2001;37(5):576-82.
2001: Aude Fléchon; Stéphane Culine; Jean Pierre Droz
Intensive and timely chemotherapy, the key of success in testicular cancer.
Critical reviews in oncology/hematology 2001;37(1):35-46.
2000: Stéphane Culine
[Gemcitabine and urothelial tumours].
Anti-cancer drugs 2000;11 Suppl 1():S9-13.
2000: F Andre; Karim Fizazi; Stéphane Culine; Jean Pierre Droz; Michel Gatineau; Y Takahashi; Stéphane Oudard; Christine Theodore
Peritoneal carcinomatosis in germ-cell tumor: relations with retroperitoneal lymph node dissection.
American journal of clinical oncology 2000;23(5):460-2.
2000: G Freyer; Philippe Rougier; Roland Bugat; J P Droz; Michel Marty; H Bleiberg; Dominique Mignard; L Awad; P Herait; Stéphane Culine; Véronique Trillet-Lenoir
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
British journal of cancer 2000;83(4):431-7.
2000: Amélie Gauvin; Frédéric Pinguet; Stéphane Culine; Cécile Astre; Roberto Gomeni; Françoise Bressolle
Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2690-5.
2000: F André; Karim Fizazi; Stéphane Culine; Jean Pierre Droz; P Taupin; Catherine Lhommé; Marie-José Terrier-Lacombe; Christine Théodore
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients.
European journal of cancer (Oxford, England : 1990) 2000;36(11):1389-94.
2000: Stéphane Culine; J P Droz
Comparative tolerability of chemotherapy regimens for germ cell cancer.
Drug safety : an international journal of medical toxicology and drug experience 2000;22(5):373-88.
2000: Ashraf Montazeri; Maud Boucaud; François Lokiec; Frédéric Pinguet; Stéphane Culine; R Déporte-Féty; Nicolas Albin; B Laguerre; Alain Goupil; Roland Bugat; Pierre Canal; Etienne Chatelut
Population pharmacokinetics of topotecan: intraindividual variability in total drug.
Cancer chemotherapy and pharmacology 2000;46(5):375-81.
2000: Frédéric Pinguet; Stéphane Culine; Françoise Bressolle; Cécile Astre; M P Serre; C Chevillard; Michel Fabbro
A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):57-63.
1999: Frédéric Pinguet; Françoise Bressolle; Stéphane Culine; Michel Fabbro; Cécile Astre; C Chevillard
Influence of the schedule of exposure on the cytotoxic effect of melphalan on human 8226 and A2780 cells.
European journal of cancer (Oxford, England : 1990) 1999;35(9):1402-6.
1999: Stéphane Culine; Michel Fabbro; Marc Ychou; Gilles Romieu; Didier Cupissol; H Pujol
Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):569-75.
1999: Stéphane Culine; I Roch; Frédéric Pinguet; Gilles Romieu; Françoise Bressolle
Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
International journal of oncology 1999;14(5):999-1006.
1999: Sophie D Fosså; Carsten Bokemeyer; Arthur Gerl; Stéphane Culine; William G Jones; Graham M Mead; J R Germa-Luch; Jörg Pont; Hans-J Schmoll; S Tjulandin
Treatment outcome of patients with brain metastases from malignant germ cell tumors.
Cancer 1999;85(4):988-97.
1999: Stéphane Culine; Andrew Kramar; Jean Pierre Droz; Christine Théodore
Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer.
The Journal of urology 1999;161(1):173-5.
1998: Stéphane Culine; M Bekradda; A Kramar; Annie Rey; Bernard Escudier; Jean Pierre Droz
Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
Cancer 1998;83(12):2548-53.
1998: Stéphane Culine; L Gazagne; Marc Ychou; Gilles Romieu; Michel Fabbro; Didier Cupissol; Jean-Bernard Dubois
[Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1998;19(10):713-9.
1998: Stéphane Culine; J Kattan; S Zanetta; Christine Théodore; Karim Fizazi; Jean Pierre Droz
Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer.
American journal of clinical oncology 1998;21(5):470-4.
1998: Karim Fizazi; Stéphane Culine
[Metastatic carcinoma of unknown origin].
Bulletin du cancer 1998;85(7):609-17.
1998: Stéphane Culine; L Abs; Marie-José Terrier-Lacombe; Christine Théodore; Pierre Wibault; Jean Pierre Droz
Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience.
European journal of cancer (Oxford, England : 1990) 1998;34(3):353-8.
1998: Karim Fizazi; Stéphane Culine; Jean Pierre Droz; Marie-José Terrier-Lacombe; Christine Théodore; Pierre Wibault; O Rixe; Pierre Ruffié; Thierry Le Chevalier
Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy?
European journal of cancer (Oxford, England : 1990) 1998;34(3):347-52.
1998: Karim Fizazi; Stéphane Culine; Jean Pierre Droz; Andrew Kramar; Christine Théodore; Pierre Ruffié; Thierry Le Chevalier
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):725-32.
1997: Stéphane Culine; Michel Fabbro; C Assens; Marc Ychou; Gilles Romieu; Andrew Kramar; Didier Cupissol; Frédéric Pinguet; H Pujol
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):951-6.
1997: Stéphane Culine; Catherine Lhommé; J P Droz
[Medical treatment of ovarian malignant germ cell tumors in the adult].
Bulletin du cancer 1997;84(9):919-21.
1997: Stéphane Culine; I Philippot; fadi farhat; Christine Théodore; Marie-José Terrier-Lacombe; Jean Pierre Droz
Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors.
Bulletin du cancer 1997;84(4):368-72.
1997: Stéphane Culine; Christine Théodore; M Bekradda; fadi farhat; Marie-José Terrier-Lacombe; Jean Pierre Droz
Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
American journal of clinical oncology 1997;20(2):184-8.
1997: Karim Fizazi; Stéphane Culine; Jean Pierre Droz; Thierry Le Chevalier; Pierre Ruffié; Christine Théodore
[Primary mediastinal non-seminomatous germ-cell tumors: from clinics to biology].
Bulletin du cancer 1997;84(3):313-27.
1997: Stéphane Culine; Christine Theodore; Marie-José Terrier-Lacombe; Jean Pierre Droz
Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
The Journal of urology 1997;157(3):855-8; discussion 858-9.
1997: Stéphane Culine; Christine Theodore; Bernard Court; JL Perrin; Jean Pierre Droz
Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
British journal of urology 1997;79(2):258-62.
1997: Frédéric Pinguet; P Martel; Michel Fabbro; I Petit; Pierre Canal; Stéphane Culine; Cécile Astre; Françoise Bressolle
Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
Anticancer research 1997;17(1B):605-11.
1997: Philippe Rougier; Roland Bugat; Jean-Yves Douillard; Stéphane Culine; E Suc; P Brunet; Y Becouarn; Marc Ychou; Michel Marty; Jean-Marc Extra; Jacques Bonneterre; Antoine Adenis; Jean-François Seitz; Gérard Ganem; Moïse Namer; Thierry Conroy; Sylvie Negrier; Yacine Merrouche; F Burki; Mireille Mousseau; P Herait; Mondher Mahjoubi
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):251-60.
1997: Stéphane Culine; Catherine Lhomme; J Kattan; G Michel; Pierre Duvillard; Jean Pierre Droz
Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience.
Gynecologic oncology 1997;64(1):160-5.
1996: Stéphane Culine; Catherine Lhomme; G Michel; J Leclere; Pierre Duvillard; Jean Pierre Droz
Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy.
Journal of surgical oncology 1996;62(1):40-5.
1996: Stéphane Culine; Christine Theodore; Marie-José Terrier-Lacombe; Jean Pierre Droz
Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy.
The Journal of urology 1996;155(4):1296-8.
1996: fadi farhat; Stéphane Culine; Catherine Lhommé; Pierre Duvillard; Patrick Soulié; G Michel; Marie-José Terrier-Lacombe; Christine Théodore; M Schreinerova; Jean Pierre Droz
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients.
Cancer 1996;77(7):1363-6.
1996: fadi farhat; Stéphane Culine; Christine Théodore; M Békradda; Marie-José Terrier-Lacombe; Jean Pierre Droz
Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Cancer 1996;77(6):1193-7.
1996: Stéphane Culine; Christine Theodore; fadi farhat; M Bekradda; Marie-José Terrier-Lacombe; Jean Pierre Droz
Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Journal of surgical oncology 1996;61(3):195-8.
1995: Stéphane Culine; C Lhomme; fadi farhat; Jean Pierre Droz
Salvage chemotherapy in non-dysgerminomatous germ cell tumours of the ovary.
European journal of cancer (Oxford, England : 1990) 1995;31A(11):1890-1.
1995: Stéphane Culine; Christine Theodore; M J Terrier-Lacombe; Jean Pierre Droz
Chemotherapy in stage II nonseminomatous germ cell tumors of the testis: The institut Gustave roussy experience.
Urologic oncology 1995;1(5):175-83.
1995: Stéphane Culine; Catherine Lhomme; Joseph Kattan; Pierre Duvillard; G Michel; Alain Gerbaulet; Jean Pierre Droz
Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy.
Gynecologic oncology 1995;58(3):344-8.
1995: fadi farhat; Stéphane Culine; C Lhomme; Pierre Duvillard; Marie-José Terrier-Lacombe; G Michel; P Soulie; Christine Theodore; J P Lotz; Jean Pierre Droz
[Desmoplastic small round cell tumors in adults: a new entity].
Bulletin du cancer 1995;82(8):665-73.
1995: L Mounedji-Boudiaf; Philippe Rougier; Stéphane Culine; Thierry de Baere; Philippe Lasser; Bernard Escudier; Michel Ducreux; E Kaloustian; Jean Pierre Droz; A Roche
[Treatment of metastatic malignant insulinomas. 2 cases].
Presse médicale (Paris, France : 1983) 1995;24(19):894-6.
1995: Stéphane Culine; Jean Pierre Droz; R Delva; B Bui; Armelle Caty; B Minier; P Mital; M Mousseau
Rapidly recycled, intensive alternating chemotherapy in heavily pretreated progressive nonseminomatous germ cell tumors a feasibility study.
Urologic oncology 1995;1(3):109-14.
1995: Bernard Escudier; Françoise Farace; Christine Théodore; Eric Angevin; Bernard Court; D Couanet; Pierre-Yves Dietrich; Stéphane Culine; Marc Pallardy; T Hercend
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute].
Bulletin du cancer 1995;82(4):296-302.
1995: Guy G. Chabot; D Abigerges; Gilles Catimel; Stéphane Culine; M de Forni; Jean-Marc Extra; Mondher Mahjoubi; P Hérait; Jean-Pierre Armand; Roland Bugat
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(2):141-51.
1995: fadi farhat; Stéphane Culine; Marie-José Terrier-Lacombe; Jean Pierre Droz
[Adenocarcinoma of rete testis. Apropos of a case and review of the literature].
Bulletin du cancer 1995;82(2):167-72.
1995: Stéphane Culine; M Bekradda; Marie-José Terrier-Lacombe; Jean Pierre Droz
Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?
European urology 1995;27(2):138-41.
1995: Joseph Kattan; Stéphane Culine; Christine Theodore; Jean Pierre Droz
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Cancer investigation 1995;13(3):276-9.
1994: Joseph Kattan; A Spatz; Stéphane Culine; Marie-José Terrier-Lacombe; Dominique Elias; Jean Pierre Droz
Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
American journal of clinical oncology 1994;17(5):390-2.
1994: L Abs; Joseph Kattan; Stéphane Culine; M Bekradda; fadi farhat; Jean Pierre Droz
[Value of mono-antibiotic therapy using piperacillin associated with sulbactam and possibly followed by vancomycin in febrile neutropenia in solid tumors].
Bulletin du cancer 1994;81(10):871-6.
1994: M de Forni; Roland Bugat; Guy G. Chabot; Stéphane Culine; Jean-Marc Extra; Alain Gouyette; Isabelle Madelaine; Michel Marty; A Mathieu-Boué
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Cancer research 1994;54(16):4347-54.
1994: A Moran-Ribon; Jean Pierre Droz; Joseph Kattan; B Leclercq; Marwan Ghosn; D Couanet; M Ostronoff; Stéphane Culine; B Misset; Bernard Escudier
Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(4):253-8.
1994: Stéphane Culine; Joseph Kattan; Catherine Lhomme; Pierre Duvillard; G Michel; Damienne Castaigne; J Leclere; J Pico; Jean Pierre Droz
A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
Gynecologic oncology 1994;54(1):47-53.
1994: L Mounedji-Boudiaf; Stéphane Culine; G Devoldère; Marie-José Terrier-Lacombe; Joseph Kattan; A Cazier; FADI SAMI FARHAT; M Bekradda; Jean Pierre Droz
[Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature].
Bulletin du cancer 1994;81(4):334-7.
1994: Stéphane Culine; Marie-José Terrier-Lacombe; Joseph Kattan; Jean Pierre Droz
[Carcinoma in situ of the testis].
Bulletin du cancer 1994;81(4):318-25.
1994: Y Chraibi; Stéphane Culine; Marie-José Terrier-Lacombe; Andrew Kramar; Joseph Kattan; Jean Pierre Droz
[Prognostic factors for extratesticular involvement in stage I testicular cancer. Apropos of 58 cases].
Bulletin du cancer 1994;81(4):311-7.
1994: fadi farhat; Joseph Kattan; Stéphane Culine; Christine Théodore; Marie-José Terrier-Lacombe; J Génin; L Mounedji-Boudiaf; M Bekradda; Jean Pierre Droz
[Liposarcoma of the spermatic cord: apropos of a case with review of the literature].
Bulletin du cancer 1994;81(3):223-5.
1994: Joseph Kattan; Stéphane Culine; T Tavakoli-Razavi; Andrew Kramar; Jean Pierre Droz
Acute tumor lysis syndrome in poor-risk germ cell tumors: does it exist?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(2):128-31.
1994: Joseph Kattan; Jean Pierre Droz; Stéphane Culine; B Escudier; C Beaumont-Raymond
Recombinant interferon-alpha efficacy in relapsed adult nephroblastoma: a case report.
The Journal of urology 1994;151(2):411-2.
1994: fadi farhat; Joseph Kattan; Stéphane Culine; M Bekradda; Jean Pierre Droz
[Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature].
Bulletin du cancer 1994;81(1):47-50.
1994: Joseph Kattan; MF Tournade; Stéphane Culine; Marie-José Terrier-Lacombe; Jean Pierre Droz
Adult Wilms' tumour: review of 22 cases.
European journal of cancer (Oxford, England : 1990) 1994;30A(12):1778-82.
1994: Stéphane Culine; Jean-Paul Guastalla; Christine Théodore; J P Droz
[Chemotherapy of urothelial tumors of the bladder].
Bulletin du cancer. Radiothérapie : journal de la Société française du cancer : organe de la société française de radiothérapie oncologique 1994;81(4):303-11.
1994: Stéphane Culine; Catherine Lhomme; Joseph Kattan; Pierre Duvillard; G Michel; Jean Pierre Droz
Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1239-44.
1993: Joseph Kattan; Stéphane Culine; Marie-José Terrier-Lacombe; Christine Théodore; Jean Pierre Droz
Paratesticular rhabdomyosarcoma in adult patients: 16-year experience at Institut Gustave-Roussy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(10):871-5.
1993: Joseph Kattan; Stéphane Culine; Christine Théodore; J P Droz
Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):793-4.
1993: Stéphane Culine; Jean-Marc Extra; Marc Espie; E Bourstyn; Véronique Dieras; S Giacchetti; C Maylin; A De Rocquancourt; F Morvan; Michel Marty
[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast].
Bulletin du cancer 1993;80(11):994-1000.
1993: Joseph Kattan; Stéphane Culine; Jean Pierre Droz; E Fadel; Bernard Court; J L Perrin; Pierre Wibault; Christine Haie-Meder
Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy.
Urology 1993;42(5):559-62.
1993: Joseph Kattan; Bernard Court; Stéphane Culine; J P Droz
[False multiple coin lesions in prostatic cancer under hormone therapy].
Presse médicale (Paris, France : 1983) 1993;22(23):1104.
1993: Joseph Kattan; Jean Pierre Droz; Stéphane Culine; Pierre Duvillard; A Thiellet; C Peillon
The growing teratoma syndrome: a woman with nonseminomatous germ cell tumor of the ovary.
Gynecologic oncology 1993;49(3):395-9.
1993: Joseph Kattan; Jean Pierre Droz; Stéphane Culine
[High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
Bulletin du cancer 1993;80(3):248-54.
1993: Jean Pierre Droz; Joseph Kattan; Marc Bonnay; Y Chraibi; M Bekradda; Stéphane Culine
High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer.
Cancer 1993;71(3 Suppl):1123-30.
1993: Andrew Kramar; Jean Pierre Droz; Annie Rey; Jeannine Bouzy; I Philippot; Stéphane Culine
Prognostic factors in non-seminomatous germ cell tumours of the testis. Experience at the Institut Gustave-Roussy.
European urology 1993;23(1):188-95.
1993: Joseph Kattan; Mondher Mahjoubi; Jean Pierre Droz; Andrew Kramar; Stéphane Culine; A Boutan-Laroze; M Chazard
High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours.
European journal of cancer (Oxford, England : 1990) 1993;29A(11):1504-9.
1992: Joseph Kattan; Jean Pierre Droz; Stéphane Culine; Vincent Ribrag; A Boutan-Laroze; Antoine Andremont
[Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy].
Bulletin du cancer 1992;79(7):705-12.
1991: Stéphane Culine; Mondher Mahjoubi; I Philippot; Jean Pierre Droz
Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin?
European journal of cancer (Oxford, England : 1990) 1991;27(12):1715.
1991: Jean-Marc Extra; F Rousseau; Stéphane Culine; S Giacchetti; Isabelle Madelaine; Michel Marty
New cytotoxic drugs in clinical development.
Nouvelle revue française d'hématologie 1991;33(6):451-6.
1990: H Lupera; Jean Pierre Droz; Stéphane Culine; J L Perrin; Bernard Court; Marwan Ghosn; M Hayat
[Cancer of the bladder after treatment with cyclophosphamide. Apropos of a case and a review of the literature].
Journal d'urologie 1990;96(1):48-52.
1989: Stéphane Culine; M Azab; F Pietri; Marwan Ghosn; B Ben Amor; H Lupera; Christine Theodore; J Renaux; Jean Pierre Droz
[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].
Bulletin du cancer 1989;76(6):583-9.